Genfit Shares Rise on Tripled Iqirvo Royalties, Extended Cash Runway

By EC Assets · Published 29 September 2026

Genfit shares advanced following news of increased royalties from its drug Iqirvo. The company’s cash reserves are now projected to extend beyond 2028. This development occurred despite a reported decrease in total revenue for the first half of the year. Genfit shares climbed as much as 4% before paring gains to close up 1.2% on Tuesday. The French pharmaceutical company specializes in liver diseases. Genfit entered the SBF 120 index in mid-September. The company's total revenue declined from 33.5 million euros to 21.1 million euros for the first half of the year. This decrease was due to the absence of milestone payments during the period. Ipsen had paid 26.5 million euros in milestones during the same period last year. That payment was for Iqirvo's pricing and reimbursement approval in Italy. Genfit deepened its losses during the first half. However, the biotech firm increased its treasury. The company indicated its treasury is more than sufficient to cover its needs. This article is intended for informational purposes only. It does not constitute investment advice.